Category: Danaher Corp.
Here's a look at some of the top regulatory stories for medical device companies this week: Johnson & Johnson eyes acquisitions in cardiovascular, elsewhere; Abbott CEO defends inversions amid corporate exodus furor; Medtronic fights tax dodging rhetoric in Covidien merger; Could Medtronic-Covidien deal get caught in anti-inversion legislation?; Siemens sells clinical microbiology biz to Beckman Coulter
Beckman Coulter picks up Siemens Healthcare Diagnostics' clinical microbiology business in a closed-doors deal.
Danaher Corp. and private equity behemoth Blackstone are joining forces in the hunt for Johnson & Johnson's Ortho Clinical Diagnostics unit, anonymous sources tell Reuters.
Shares of Danaher Corp. rise after it beats Wall Street's earnings forecast and affirms its outlook for the rest of the year.
Danaher (NYSE:DHR) shares gained today after the conglomerate shattered Wall Street's 3rd-quarter earnings expectations and affirmed its outlook for the balance of 2013.
Johnson & Johnson puts its Ortho Clinical Diagnostics blood testing business on the auction block.
Share of Danaher Corp. are down today after the company reports 2nd-quarter results and narrows its earnings forecast for the rest of the year.
Danaher (NYSE:DHR) shares are down today on a narrowed earnings outlook for the rest of the year, after the conglomerate reported modest 2nd-quarter sales and earnings growth.
Danaher posts adjusted per-share earnings just a penny shy of Wall Street's consensus estimate, and the company's shares lose 2.5%.
Washington-based Danaher (NYSE:DHR) posted gains in its 1st-quarter 2013 sales and profits, but fell a penny short of analysts' earning expectations for the 3 months ended March 29, 2013.